Press release
Gastric Cancer Market Size And Global Industry Forecast 2034
Gastric Cancer Market
Introduction
The Gastric Cancer Market focuses on one of the most prevalent and deadly malignancies worldwide, particularly in East Asia, Eastern Europe, and parts of South America. Gastric cancer, also known as stomach cancer, is often diagnosed in advanced stages due to non-specific early symptoms, making it a significant public health challenge.
Over the past decade, advancements in molecular diagnostics, targeted therapies, immunotherapy, and minimally invasive surgery have improved survival rates, especially for patients with HER2-positive or PD-L1-positive tumors. The next decade will see accelerated growth driven by precision oncology, liquid biopsy adoption, and integration of AI-based diagnostic tools into gastric cancer care.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70854
Market Overview
• Market Size 2024: USD 5.9 billion
• Forecast 2034: USD 10.2 billion
• CAGR (2024-2034): 5.6%
Key Highlights:
• Growing adoption of trastuzumab and immunotherapies for advanced gastric cancer.
• Rising use of laparoscopic and robotic-assisted gastrectomy for early-stage disease.
• Expanding application of next-generation sequencing (NGS) for biomarker-driven treatment.
• Asia-Pacific accounts for the highest incidence and fastest market growth.
Market Drivers:
• High prevalence in countries like Japan, China, and South Korea.
• Increasing government investment in cancer screening and prevention programs.
• Strong pipeline of targeted therapies and immuno-oncology drugs.
Market Challenges:
• Late-stage diagnosis in the majority of patients.
• Limited access to advanced treatments in low-income regions.
• Resistance development to targeted and immunotherapies.
Leading Players:
• Roche Holding AG
• Bristol Myers Squibb (BMS)
• AstraZeneca plc
• Merck & Co., Inc.
• Novartis AG
• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Zymeworks Inc.
• BeiGene, Ltd.
Segmentation Analysis
By Product
• Chemotherapy Agents
• Targeted Therapy (HER2 Inhibitors, VEGF Inhibitors, CLDN18.2 Inhibitors)
• Immunotherapy (PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitors)
• Diagnostic Kits & Reagents
• Surgical Devices
By Platform
• Pharmaceuticals
• Diagnostics
• Medical Devices
By Technology
• Endoscopic Screening
• Next-Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• Liquid Biopsy
• Robotic-Assisted Surgery
By End Use
• Hospitals
• Specialty Oncology Clinics
• Diagnostic Laboratories
• Ambulatory Surgical Centers
By Application
• Early-Stage Gastric Cancer
• Advanced/Metastatic Gastric Cancer
Segmentation Summary:
Pharmaceuticals dominate due to strong demand for chemotherapy, targeted agents, and immunotherapies. Diagnostics are gaining market share as screening programs expand, particularly in high-risk regions.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70854
Regional Analysis
North America
• Moderate prevalence but high adoption of targeted and immunotherapies.
• U.S. leads in clinical trial activity for novel gastric cancer treatments.
Europe
• Strong adoption of biomarker testing and personalized therapy.
• Germany, France, and the UK lead in treatment innovation.
Asia-Pacific
• Largest and fastest-growing market due to high disease incidence, advanced screening programs, and strong adoption of novel therapies.
• Japan and South Korea have long-standing national screening programs for early detection.
Middle East & Africa
• Low awareness and limited access to advanced treatments.
• Gradual improvements in oncology care in major urban centers.
Latin America
• Brazil, Mexico, and Argentina driving regional growth with expanding oncology infrastructure.
• Partnerships with global pharma companies increasing treatment availability.
Regional Trends Summary:
Asia-Pacific is the largest market and growth leader, while North America and Europe remain at the forefront of drug innovation and clinical trials.
Market Dynamics
Key Growth Drivers
• High incidence in Asia-Pacific driving strong demand for screening and treatment.
• Biomarker-driven therapy adoption improving survival rates.
• Technological innovations in endoscopy and surgical robotics.
Key Challenges
• Late diagnosis limiting treatment effectiveness.
• Resistance to HER2 and PD-1/PD-L1 inhibitors.
• Healthcare disparities affecting access to novel therapies.
Latest Trends
• Expansion of CLDN18.2-targeted therapies in clinical trials.
• Use of AI in endoscopy for early detection of gastric lesions.
• Increasing application of liquid biopsy for minimal residual disease monitoring.
• Growing real-world evidence studies to optimize treatment sequencing.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70854/gastric-cancer-market
Competitor Analysis
Major Players:
1. Roche Holding AG - Herceptin, Tecentriq
2. Bristol Myers Squibb - Opdivo
3. AstraZeneca plc - Imfinzi, Enhertu (collaboration)
4. Merck & Co., Inc. - Keytruda
5. Novartis AG - Targeted oncology pipeline
6. Eli Lilly and Company - Cyramza
7. Pfizer Inc. - Targeted gastric cancer research
8. Amgen Inc. - Oncology pipeline
9. Zymeworks Inc. - Bispecific antibody development
10. BeiGene, Ltd. - PD-1 inhibitors
Competitive Summary:
The market is competitive, with Roche, Merck, and BMS leading in approved therapies, while Asian companies like BeiGene are gaining prominence in immuno-oncology. Partnerships between Western and Asian firms are key to expanding access in high-incidence regions.
Conclusion
The Gastric Cancer Market is projected to grow from USD 5.9 billion in 2024 to USD 10.2 billion by 2034, at a CAGR of 5.6%. The future of gastric cancer care lies in early detection, biomarker-driven precision therapy, and integration of AI and liquid biopsy technologies.
This report is also available in the following languages : Japanese (胃がん市場), Korean (위암 시장), Chinese (胃癌市场), French (Marché du cancer gastrique), German (Markt für Magenkrebs), and Italian (Mercato del cancro gastrico), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70854
Our More Report:
Chlorella Supplements
https://exactitudeconsultancy.com/reports/65947/chlorella-supplements-market
Pediatric MRI Systems
https://exactitudeconsultancy.com/reports/65949/pediatric-mri-systems-market
Collagen Jelly
https://exactitudeconsultancy.com/reports/65945/collagen-jelly-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastric Cancer Market Size And Global Industry Forecast 2034 here
News-ID: 4143904 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for Gastric
Rising Gastric Cancer Cases Fuel Growth In Gastric Cancer Drugs Market Driving M …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Gastric Cancer Drugs Market Size By 2025?
In recent times, the market size for gastric cancer drugs has seen a swift expansion. Projections forecast growth from $4.41 billion in 2024 to $4.9 billion in 2025, a compound annual growth rate (CAGR) of 11.2%. Factors contributing…
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driving Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Gastric Ulcers Market Size By 2025?
In the last few years, the market size for gastric ulcers has been expanding notably. It is anticipated to increase from $4.29 billion in 2024 to $4.54 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.9%.…
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driver: Leadi …
How Are the key drivers contributing to the expansion of the gastric ulcers market?
The rising geriatric population is expected to accelerate the growth of the gastric ulcers market. The geriatric population, typically individuals aged 65 and above, is growing due to improvements in healthcare and increased life expectancy. This population is more susceptible to gastric ulcers due to factors like the use of NSAIDs and decreased mucosal protection. For instance,…
Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Ca …
What market dynamics are playing a key role in accelerating the growth of the gastric cancer drugs market?
The rise in obesity and smoking rates has led to an increased prevalence of gastric cancer. Factors like tobacco use and poor dietary habits have been linked to a higher risk of developing this disease. As per data from the Government Digital Service in the UK, it was projected in May 2023 that…
Gastric Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer…
Gastric Function Test Market - Empowering Digestive Health: Gastric Function Tes …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gastric Function Test Market.
Gastric Function Test Market: https://www.growthplusreports.com/report/gastric-function-test-market/9126
The Gastric Function Test Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
